



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION



## Sphingosine Kinase 2 (human, recombinant)

Item No. 30191

### Overview and Properties


**Synonyms:** SK2, SPHK2, SPK2  
**Source:** Active recombinant N-terminal His-tagged protein expressed in insect cells  
**Amino Acids:** 2-654 (full length)  
**Uniprot No.:** Q9NRAO  
**Molecular Weight:** 72.9 kDa  
**Storage:** -80°C (as supplied)  
**Stability:** ≥1 year  
**Purity:** *batch specific* (≥75% estimated by SDS-PAGE)  
**Supplied in:** 25 mM HEPES, pH 8.0, with 150 mM sodium chloride, 3 mM DTT, 0.05% Triton X-100, and 5% glycerol

### Protein

**Concentration:** *batch specific* mg/ml  
**Activity:** *batch specific* U/ml  
**Specific Activity:** *batch specific* U/mg  
**Unit Definition:** One unit is defined as the amount of enzyme required to produce 1 μmol of ADP per minute at 25°C in 20 mM HEPES, pH 7.4, containing 50 mM sodium chloride, 10 mM magnesium chloride, 1 mM EGTA, 0.02% triton X-100, and 50 μM sphingosine (d18:1).


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Images



Lane 1: MW Markers  
Lane 2: SPHK2 (4 μg)  
Lane 3: SPHK2 (2 μg)

Representative gel image shown; actual purity may vary between each batch.



WARNING  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/22/2020

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM

# PRODUCT INFORMATION



## Description

Sphingosine kinase 2 (SPHK2) is an ATP-dependent lipid kinase that is encoded by the *SPHK2* gene in humans.<sup>1</sup> It is composed of an N-terminal domain that contains an ATP binding site and a C-terminal domain that mediates substrate binding and specificity. SPHK2 is localized to the mitochondria, nucleus, and endoplasmic reticulum and is expressed in a wide variety of tissues, including the liver and kidney.<sup>2</sup> Upon cellular stimulation with EGF, phorbol 12-myristate 13-acetate (PMA; Item No. 10008014), or FcεRI, SPHK2 is activated and catalyzes phosphorylation of sphingosine to sphingosine-1-phosphate (S1P).<sup>1,3</sup> SPHK2 has roles in many physiological and pathological processes, including cancer, inflammation, and neurodegenerative diseases.<sup>1,4-7</sup> Pharmacological inhibition of SPHK2 decreases intracellular S1P levels in U937 cells, but genetic deletion or pharmacological inhibition of SPHK2 in mice increases blood S1P levels, an effect that has not been fully characterized but may be related to reduced S1P clearance in the blood in the absence of SPHK2 activity.<sup>8</sup> Overexpression of *SPHK2* increases intracellular calcium levels and induces apoptosis in NIH3T3 cancer cells and reduces LPS-induced increases in TNF-α and IL-6 levels in isolated human peripheral blood mononuclear cell-derived macrophages *in vitro*.<sup>4,5</sup> SPHK2 activity is increased in postmortem frontal cortex from patients with Alzheimer's disease.<sup>7</sup> Cayman's Sphingosine Kinase 2 (human, recombinant) protein can be used for Western blot, ELISA, and enzymatic assays.

## References

1. Hatoum, D., Haddadi, N., Lin, Y., *et al.* Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: Challenges for SphK as an oncotarget. *Oncotarget* **8(22)**, 36898-36929 (2017).
2. Liu, H., Sugiura, M., Nava, V.E., *et al.* Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. *J. Biol. Chem.* **275(26)**, 19513-19520 (2000).
3. Hait, N.C., Bellamy, A., Milstien, S., *et al.* Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. *J. Biol. Chem.* **282(16)**, 12058-12065 (2007).
4. Maceyka, M., Sankala, H., Hait, N.C., *et al.* SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. *J. Biol. Chem.* **280(44)**, 37118-37129 (2005).
5. Weigert, A., von Knethen, A., Thomas, D., *et al.* Sphingosine kinase 2 is a negative regulator of inflammatory macrophage activation. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **1864(9)**, 1235-1246 (2019).
6. Samy, E.T., Meyer, C.A., Caplazi, P., *et al.* Cutting edge: Modulation of intestinal autoimmunity and IL-2 signaling by sphingosine kinase 2 independent of sphingosine 1-phosphate. *J. Immunol.* **179(9)**, 5644-5648 (2007).
7. Takasugi, N., Sasaki, T., Suzuki, K., *et al.* BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. *J. Neurosci.* **31(18)**, 6850-6857 (2011).
8. Kharel, Y., Morris, E.A., Congdon, M.D., *et al.* Sphingosine kinase 2 inhibition and blood sphingosine 1-phosphate levels. *J. Pharmacol. Exp. Ther.* **355(1)**, 23-31 (2015).